Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) and CEL-SCI (NYSE:CVM – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
Risk & Volatility
Tectonic Therapeutic has a beta of 2.63, meaning that its stock price is 163% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.
Valuation and Earnings
This table compares Tectonic Therapeutic and CEL-SCI”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tectonic Therapeutic | N/A | N/A | $12.16 million | ($5.89) | -4.37 |
| CEL-SCI | N/A | N/A | -$26.92 million | ($0.51) | -0.76 |
Profitability
This table compares Tectonic Therapeutic and CEL-SCI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tectonic Therapeutic | N/A | -35.53% | -31.97% |
| CEL-SCI | N/A | -228.43% | -100.46% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Tectonic Therapeutic and CEL-SCI, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tectonic Therapeutic | 0 | 0 | 5 | 1 | 3.17 |
| CEL-SCI | 0 | 0 | 0 | 0 | 0.00 |
Tectonic Therapeutic presently has a consensus price target of $72.25, suggesting a potential upside of 180.91%. Given Tectonic Therapeutic’s stronger consensus rating and higher possible upside, equities analysts plainly believe Tectonic Therapeutic is more favorable than CEL-SCI.
Institutional and Insider Ownership
62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 12.1% of CEL-SCI shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 16.2% of CEL-SCI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Tectonic Therapeutic beats CEL-SCI on 9 of the 12 factors compared between the two stocks.
About Tectonic Therapeutic
Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.
About CEL-SCI
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Receive News & Ratings for Tectonic Therapeutic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tectonic Therapeutic and related companies with MarketBeat.com's FREE daily email newsletter.
